Valneva Reports Adverse Audit Opinion on Internal Controls, Withdraws US Chikungunya Vaccine Amid Widening Losses

summarizeSummary

Valneva received an adverse audit opinion on internal controls and voluntarily withdrew its chikungunya vaccine (IXCHIQ) from the US market due to safety concerns, contributing to a widened net loss in 2025, despite securing new debt financing.

check_boxKey Events

• Adverse Audit Opinion on Internal Controls

  Auditors issued an adverse opinion on the effectiveness of internal control over financial reporting as of December 31, 2025, citing a material weakness related to complex, judgmental, and non-recurring transactions.

• US Chikungunya Vaccine (IXCHIQ) Withdrawn

  Valneva voluntarily withdrew its BLA and IND for IXCHIQ in the United States in January 2026 due to serious safety concerns, including a fatal case directly attributable to the vaccine. Other regulators (MHRA, ANVISA) also restricted its use.

• Net Loss Widens Significantly in 2025

  The company reported a net loss of €115.2 million for 2025, a substantial increase from the €12.2 million loss in 2024, and an operating loss of €82.1 million, reversing a profit from the prior year.

• New Non-Dilutive Debt Facility Secured

  In October 2025, Valneva secured a new non-dilutive debt facility of up to $500 million with Pharmakon Advisors, with an initial $215 million tranche used to repay existing debt, extending maturity to Q4 2030.

auto_awesomeAnalysis

Valneva SE's annual report reveals critical issues impacting its financial reporting and key product pipeline. Auditors issued an adverse opinion on the effectiveness of internal controls over financial reporting due to a material weakness, indicating a significant risk of financial misstatement. Operationally, the company voluntarily withdrew its Biologics License Application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ, in the United States in January 2026 due to serious safety concerns, including a vaccine-attributable fatality. This follows other regulatory restrictions on IXCHIQ in the UK and Brazil. Financially, the company reported a significantly widened net loss of €115.2 million in 2025, compared to a €12.2 million loss in 2024. While a new non-dilutive debt facility of up to $500 million was secured in October 2025, providing liquidity, the overall picture is one of significant regulatory and financial challenges. Investors should closely monitor the remediation of internal control weaknesses, the future of IXCHIQ in other markets, and the upcoming Phase 3 results for the Lyme disease vaccine candidate (VLA15) in H1 2026, which is a critical catalyst for the company's future.